Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

Introgen Therapeutics

Status and phase: Unknown; Phase 2

Conditions: Malignant Melanoma; Neoplasm Metastasis

Treatments: Genetic: investigational drug INGN 241

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00116363

INT 241-004

2003-0590, R43 CA 89778

Details and patient eligibility

About

This is a research study to look at the ways in which a treatment called INGN241 can kill melanoma cells or help the patient's immune system kill melanoma cells.

Full description

INGN 241 is an adenoviral vector carrying the MDA-7 cDNA. MDA-7 is a novel tumor suppressor molecule with cytokine properties, recently designated as IL-24. Over expression of MDA-7 in melanoma cells in vitro has been shown to inhibit cellular proliferation and induce apoptosis. Loss of MDA-7 expression in human melanomas has been shown to correlate with invasion and metastasis. The INGN 241 gene transfer construct has been previously used in human subjects in an ongoing open label Phase I study using intratumoral administration, and has been well tolerated to date. The primary objectives of the present study are to determine if INGN 241, injected into a melanoma in transit lesion, can induce apoptosis in regional uninjected lesions and initiate systemic immune activation. Secondary objectives include examination of specific immunity and of clinical response and toxicity.

Enrollment: 25 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically proven melanoma, must have 3 regional metastatic lesions that are in transit

Exclusion criteria

• Central nervous system involvement by melanoma

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)